FILTER
FILTERED INTERVIEW RESULTS
Christiana Bardon
CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL
"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."
Debbie Hart
PRESIDENT AND CEO, BIONJ
"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.
"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."
Robert Poe
CEO, OLON RICERCA BIOSCIENCES
"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."
Manni Kantipudi & Ramesh Subramanian
CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES
"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."
Chris Garabedian
CHAIRMAN AND CEO, XONTOGENY, AND PORTFOLIO MANAGER, PERCEPTIVE XONTOGENY VENTURE (PXV) FUND
"Following a long period of significant investment in early-stage firms, our industry needs to allow existing investments across the industry to mature and show signs of success before driving new investments in preclinical-stage projects."
Tom Wilson
GLOBAL BUSINESS DEVELOPMENT LEAD, PFIZER CENTREONE
"As we get into precision medicines, therapies, parallel trials, and getting medicines to patients faster, that will require CDMOs to work together, and this is where our growth will come from."
Fabrice Panza
MANAGER GLOBAL COOL CHAIN SOLUTIONS, ETIHAD CARGO
"Etihad Cargo’s PharmaLife product has exponentially grown over the past year, and growth will trigger more physical ties between US and UAE."
James Sapirstein
CHAIRMAN, PRESIDENT, AND CEO, FIRST WAVE BIOPHARMA
“We are happy to report that we have initiated the Phase 2 SPAN adrulipase clinical and are currently screening patients for the study. We anticipate topline data by mid-2023.”
Kendalle O’Connell
CEO AND PRESIDENT, MASSBIO
"In 2022, Massachusetts received 25% of all biopharma VC funding in the US. We are seeing new clusters emerge outside the traditional hubs of Kendall Square and Boston."
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
Africa Energy 2024 - Pre-release
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
The pre-release edition of Africa Energy 2024 comprises analysis based on over 80 interviews with ministers and leading executives from IOCs, NOCs, independents, associations, investors and service providers, to provide an in-depth and holistic view of sub-Saharan Africa’s ever-evolving energy sector.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
